Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients
This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis. Thirty‐one patients were included. The Ankylosing Spondylitis Disease Activity Score improved with increasing adalimumab trough level at week 12 and reached a major improvement with levels between 8 and 12 μg/mL. Moreover, weeks 4 and 2 adalimumab levels below 4.28 and 3.37 μg/mL were predictive of primary nonresponse (area under the curve (AUC) = 0.89, 0.88; P = 0.0003, P = 0.034, respectively). Week 4 AAA signal‐to‐noise levels were significantly higher among primary nonresponders, and the cutoff for primary nonresponse prediction was above 5.31 (AUC = 0.81; P = 0.004). Adalimumab trough levels in a range of 8–12 μg/mL are optimum to reach major improvement, and lower adalimumab with higher AAA levels at the early stage (week 4) predict primary nonresponse by supporting proactive monitoring to optimize adalimumab therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical and Translational Science - 13(2020), 3, Seite 547-554 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiaoliang Ding [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1111/cts.12738 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ078068886 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ078068886 | ||
| 003 | DE-627 | ||
| 005 | 20230309154907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cts.12738 |2 doi | |
| 035 | |a (DE-627)DOAJ078068886 | ||
| 035 | |a (DE-599)DOAJ5e8b18d083ad4ac5a2586d3789853132 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a RA1-1270 | |
| 100 | 0 | |a Xiaoliang Ding |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early Adalimumab and Anti‐Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a This study aimed at exploring the concentration‐effect relationship of adalimumab and early adalimumab and anti‐adalimumab antibody (AAA) levels in predicting primary nonresponse in a real‐world pilot cohort of patients with ankylosing spondylitis. Thirty‐one patients were included. The Ankylosing Spondylitis Disease Activity Score improved with increasing adalimumab trough level at week 12 and reached a major improvement with levels between 8 and 12 μg/mL. Moreover, weeks 4 and 2 adalimumab levels below 4.28 and 3.37 μg/mL were predictive of primary nonresponse (area under the curve (AUC) = 0.89, 0.88; P = 0.0003, P = 0.034, respectively). Week 4 AAA signal‐to‐noise levels were significantly higher among primary nonresponders, and the cutoff for primary nonresponse prediction was above 5.31 (AUC = 0.81; P = 0.004). Adalimumab trough levels in a range of 8–12 μg/mL are optimum to reach major improvement, and lower adalimumab with higher AAA levels at the early stage (week 4) predict primary nonresponse by supporting proactive monitoring to optimize adalimumab therapy. | ||
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Public aspects of medicine | |
| 700 | 0 | |a Ruifang Zhu |e verfasserin |4 aut | |
| 700 | 0 | |a Jian Wu |e verfasserin |4 aut | |
| 700 | 0 | |a Ling Xue |e verfasserin |4 aut | |
| 700 | 0 | |a Meihua Gu |e verfasserin |4 aut | |
| 700 | 0 | |a Liyan Miao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Clinical and Translational Science |d Wiley, 2016 |g 13(2020), 3, Seite 547-554 |w (DE-627)DOAJ00007795X |x 17528062 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:3 |g pages:547-554 |
| 856 | 4 | 0 | |u https://doi.org/10.1111/cts.12738 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/5e8b18d083ad4ac5a2586d3789853132 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1111/cts.12738 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1752-8054 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1752-8062 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 3 |h 547-554 | ||